The Follicular Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Follicular Lymphoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Follicular Lymphoma Market.
Some of the key takeaways from the Follicular Lymphoma Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Follicular Lymphoma treatment therapies with a considerable amount of success over the years.
-
Follicular Lymphoma companies working in the treatment market are InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy’s Laboratories, MAB WORKS, and others, are developing therapies for the Follicular Lymphoma treatment
-
Emerging Follicular Lymphoma therapies in the different phases of clinical trials are- ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others are expected to have a significant impact on the Follicular Lymphoma market in the coming years.
-
In February 2024, The FDA has granted Priority Review to AbbVie and Genmab’s Epkinly (epcoritamab) for a supplemental biologics license application (sBLA) aimed at treating difficult-to-treat relapsed or refractory (r/r) follicular lymphoma (FL), a slow-growing type of lymphoma, after at least two prior lines of systemic therapy. Despite the emergence of new treatments and chimeric antigen receptor (CAR)-T cell therapy, there remains a substantial unmet need for managing r/r FL with effective and more convenient therapies, which Epkinly aims to address.
-
IN November 2023, Bayer, a multinational pharmaceutical company based in Germany, has revealed intentions to voluntarily retract its new drug application in the United States for Aliqopa (copanlisib) in the treatment of relapsed follicular lymphoma (FL) due to an unsuccessful trial. This determination follows discussions between the company and the US Food and Drug Administration (FDA) regarding the trial data for Aliqopa’s efficacy.
Follicular Lymphoma Overview
Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma (NHL), a cancer that originates in the lymphatic system, which is part of the body’s immune system. FL specifically arises from abnormal B-lymphocytes, a type of white blood cell, and typically grows slowly over time.
Get a Free Sample PDF Report to know more about Follicular Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight
Emerging Follicular Lymphoma Drugs Under Different Phases of Clinical Development Include:
-
ICP 248: InnoCare Pharma
-
ALLO-501: Allogene Therapeutics
-
HMPL-689: HUTCHMED
-
PSB 202: Sound Biologics
-
Abexinostat: Xynomic Pharmaceuticals
-
Loncastuximab tesirine: ADC Therapeutics
-
Acalabrutinib: AstraZeneca
-
DRL_RI: Dr Reddy’s Laboratories
-
MIL62: MAB WORKS
Follicular Lymphoma Route of Administration
Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Follicular Lymphoma Molecule Type
Follicular Lymphoma Products have been categorized under various Molecule types, such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Follicular Lymphoma Pipeline Therapeutics Assessment
-
Follicular Lymphoma Assessment by Product Type
-
Follicular Lymphoma By Stage and Product Type
-
Follicular Lymphoma Assessment by Route of Administration
-
Follicular Lymphoma By Stage and Route of Administration
-
Follicular Lymphoma Assessment by Molecule Type
-
Follicular Lymphoma by Stage and Molecule Type
DelveInsight’s Follicular Lymphoma Report covers around 50+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Follicular Lymphoma product details are provided in the report. Download the Follicular Lymphoma pipeline report to learn more about the emerging Follicular Lymphoma therapies
Some of the key companies in the Follicular Lymphoma Therapeutics Market include:
Key companies developing therapies for Follicular Lymphoma are – Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, ADC Therapeutics, Incyte Corporation, MorphoSys, AbbVie, Janssen Research & Development, Regeneron Pharmaceuticals, Novartis, MEI Pharma, BeiGene, Xynomic Pharmaceuticals, Bristol Myers Squibb, and others.
Follicular Lymphoma Pipeline Analysis:
The Follicular Lymphoma pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Follicular Lymphoma with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.
-
Follicular Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Follicular Lymphoma drugs and therapies
Follicular Lymphoma Pipeline Market Drivers
-
Increase in prevalence of Follicular Lymphoma, emergence of effective novel therapies, increased Research and Developmental Activities are some of the important factors that are fueling the Follicular Lymphoma Market.
Follicular Lymphoma Pipeline Market Barriers
-
However, lack Of Cost-Effective Treatment, progression of disease within 2 years (POD24) in the Disease and other factors are creating obstacles in the Follicular Lymphoma Market growth.
Scope of Follicular Lymphoma Pipeline Drug Insight
-
Coverage: Global
-
Key Follicular Lymphoma Companies: InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy’s Laboratories, MAB WORKS, and others
-
Key Follicular Lymphoma Therapies: ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others
-
Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
-
Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers
Request for Sample PDF Report for Follicular Lymphoma Pipeline Assessment and clinical trials
Table of Contents
1. Follicular Lymphoma Report Introduction
2. Follicular Lymphoma Executive Summary
3. Follicular Lymphoma Overview
4. Follicular Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. Follicular Lymphoma Pipeline Therapeutics
6. Follicular Lymphoma Late Stage Products (Phase II/III)
7. Follicular Lymphoma Mid Stage Products (Phase II)
8. Follicular Lymphoma Early Stage Products (Phase I)
9. Follicular Lymphoma Preclinical Stage Products
10. Follicular Lymphoma Therapeutics Assessment
11. Follicular Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Follicular Lymphoma Key Companies
14. Follicular Lymphoma Key Products
15. Follicular Lymphoma Unmet Needs
16 . Follicular Lymphoma Market Drivers and Barriers
17. Follicular Lymphoma Future Perspectives and Conclusion
18. Follicular Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/